Galenica news for suppliers
Earlier
-
Half-year sales rise 7.1%, with pharmacy revenue up 6.2%
Galenica’s sales rose 7.1% to CHF 2,136.5 million in the first half of 2026. Pharmacy revenue increased 6.2% to CHF 756.9 million, excluding Coop Vitality. The Swiss consumer healthcare market grew 0.2%, with weaker demand for cold and pain medicines and growth from allergy products, vitamins and minerals.
-
Sales rise 7.3% as pharmacy and wholesale businesses grow
Galenica’s sales rose 7.3% to CHF 1,409.7 million in January–April 2026, driven mainly by pharmacies and wholesale. The pharmacy network grew by a net two locations to 383, including Coop Vitality. Sales of cold and pain medicines fell, while online sales and Click & Collect recorded above-average growth.